Skip to Main Content

Paper Details

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Cancer Cell
394
2021
ASCL1, Aurora kinases, BCL-2, Cisplatin, Inflamed gene signature, NEUROD1, PARP, POU2F3, SCLC, SCLC subtypes, SCLC-, SCLC-A, SCLC-A patient-derived xenografts, SCLC-A, N, P, and I, SCLC-I, patient, patients, platinum, small cell lung cancer, tumor
Author NameAffiliation
Lixia Diaothe University of Texas MD Anderson Cancer Center
Paul Robson
John D MinnaDepartment of Internal Medicine and Simmons Cancer Center, the University of Texas Southwestern Medical Center
  • 1 - 3

Datasets

Release 1.2